FDA approves phase 1/2 clinical trial with ABX196 in patients with liver cancer ABX196 to be tested in combination with checkpoint inhibitor nivolumab to treat hepatocellular carcinoma
May 14, 2019
LA JOLLA, CA The U.S. Food and Drug Administration has approved an investigational new drug (IND) application for a phase 1/2 clinical trial of ABX196, a liver cancer therapy developed in the laboratory of Scripps Research Professor Luc Teyton, MD, PhD, and licensed to French pharmaceutical company Abivax.
The FDA approval allows Abivax testing of ABX196 in patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. ABX196 showed potent efficacy against HCC in preclinical testing.
The translation of basic research discoveries to the clinic is the greatest achievement we can hope for as clinician scientists. says Teyton, who is also a member of Abivax's Scientific Advisory Board. The use of ABX196 in the context of immunotherapy has been shown to be beneficial in multiple animal models of cancer, but the results with hepatocellular carcinoma are spectacular. We are looking forward to impacting the disease in patients, especially given the limitations of current therapies.
The open IND allows Abivax to test ABX196 in combination with nivolumab (Opdivo, Bristol-Myers Squibb), a checkpoint inhibitor, in a first phase 1/2 clinical trial to treat patients with HCC. The initial dose-escalation phase of the study will be conducted at the Scripps MD Anderson Cancer Center in San Diego, California, USA; additional leading cancer centers in the U.S. will be involved in the subsequent expansion phase of the study. The first patient is expected to be enrolled this summer.
We are thrilled to have been given the green light by FDA for our U.S. study. says Hartmut J. Ehrlich, MD, chief executive officer of Abivax. This open IND allows Abivax, in collaboration with leading key opinion leaders at internationally renowned U.S. cancer centers of excellence, to explore the clinical potential of our iNKT agonist ABX196 to broaden and potentiate the activity of the checkpoint inhibitor nivolumab. Based on its unique mechanism of action and exciting preclinical data in several cancer models, we believe ABX196 is a promising immunotherapeutic product candidate for patients with liver cancer that may also have potential in other cancers.
ABX196 is a synthetic glycolipid agonist of invariant natural killer T cells (iNKT) in a liposomal formulation. A phase 1 clinical trial conducted by Abivax in healthy volunteers has been completed and demonstrated safety and tolerability as well as a potent activation of iNKT cells. ABX196, both alone and in combination with a checkpoint inhibitor, showed a statistically highly significant therapeutic effect in reducing tumor growth as measured by MRI and increasing survival in mice with HCC. Abivax holds exclusive rights to ABX196 from Scripps Research, the University of Chicago, and Brigham Young University.
Despite the recent introduction of checkpoint inhibitors, hepatocellular carcinoma continues to be a substantial therapeutic challenge, as only about 20 percent of the treated patients show a response to these new drugs says Darren Sigal, MD, program director of GI Oncology at Scripps Clinic and Scripps MD Anderson Cancer Center in San Diego, and principal investigator of the study. While checkpoint inhibitors block a do not attack me' signal on cancer cells, ABX196 activates iNKT cells, a subpopulation of lymphocytes that is critical for mounting an effective immune response. The synergy between these two molecules carries substantial promise for improved outcomes for patients with this deadly cancer.
Checkpoint inhibitors like nivolumab are a leading class of therapeutic monoclonal antibodies that block certain endogenous proteins (PD-1/PDL-1) made by immune cells, such as T cells, as well as some cancer cells. These proteins effectively hijack the immune system, causing it to keep immune responses in check and preventing T cells from killing cancer cells. When these proteins are blocked, the brakes on the immune system are released and T cells are able to kill cancer cells much more efficiently. In some cancers, treatment with checkpoint inhibitors has been highly efficacious. However, due to the tumor micro-environment in other cancers, such as HCC, checkpoint inhibitors can have difficulties exerting their effects. ABX196 is intended as a drug that will potentiate the efficacy of checkpoint inhibitors by activating iNKT cells to kill tumor cells.
HCC is the most common form (75 to 90 percent) of primary liver cancer in adults. It typically occurs in the setting of chronic liver inflammation and/or cirrhosis and is closely linked to chronic viral infection such as hepatitis B or C, exposure to toxins such as alcohol, and to certain diseases such as non-alcoholic steatohepatitis (NASH).
The incidence of and deaths related to HCC are increasing in the United States and globally due to hepatitis B and C virus infections, as well as NASH. Prevalence data from 2018 show a total of 79,000 cases of HCC in the U.S. and G5 Europe (Germany, France, Italy, Spain and the UK), with 67,000 new cases, and a total of 260,000 cases in China with 338,000 new cases. Globally, there were 841,000 new cases of liver cancer (ranking it sixth of all reported cancers) and 782,000 fatalities (ranking it fourth) in 2018.
Currently, the American Cancer Society reports five-year survival rates in the U.S. of 31 percent for localized HCC, 11 percent for regional, and 2 percent for distant or metastatic, indicating a clear unmet medical need for improved therapies for HCC.
Cancer Immunology & Microbiology Teyton, Luc
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
04/08/2026
Dalet, a leading technology and service provider for media-rich organizations, t...
04/07/2026
April 7 2026, 19:00 (PDT) Detective Conan: Fallen Angel of the Highway Opens in...
01/06/2026
January 6 2026, 05:30 (PST) Dolby Sets the New Standard for Premium Entertainment at CES 2026
Throughout the week, Dolby brings to life the latest innovatio...
19/05/2026
Actus Digital, a LiveU company, and a leading provider of intelligent media monitoring and broadcast compliance platforms, announced today that METEO CONSULT ha...
19/05/2026
Globecast, a leading provider of managed services for the broadcast and media industry, today announced the completion of a major renovation of its Singapore fa...
19/05/2026
Following a major upgrade to its Connecticut remote production centre with the installation of three 60-fader Argo S consoles in 2023, RPS has switched one of t...
19/05/2026
PlayBox Technology today announced the launch of Celebro Play, a browser-based media orchestration platform designed specifically for broadcast facilities and p...
19/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/05/2026
LYNX Technik, provider of modular signal processing solutions for broadcast, post, and professional AV will showcase its latest signal processing solutions at B...
19/05/2026
Media Links, a leading developer and manufacturer of IP media transport solutions, has announced the integration of its Xscend platform with Skyline Communicat...
19/05/2026
Collaboration expands regional partner ecosystem as Media Links showcases IP media transport solutions on stand 4M4-4 and alongside Clearcast Asia on stand
Me...
19/05/2026
Company Highlights Labor-Saving Control and Custom Branding Opportunities Designed to Increase Integrator Profitability
LynTec, a leading manufacturer of ele...
19/05/2026
Mago Studio Moves AI Video Beyond Prompts with New Production-Focused Tools
Brie Clayton May 18, 2026
0 Comments
New Capabilities Bring Controllable, ...
19/05/2026
It May be Time to Stop and Take an AI Breather
Brie Clayton May 19, 2026
0 Comments
If the rock you stay on starts to roll, jump clean. Or you'll...
18/05/2026
Despite a bumpy start to the year, the provider of event-production support and ...
18/05/2026
Daktronics has partnered with the University of North Carolina to manufacture and install 11 LED displays totaling more than 10,000 square feet and more than 14...
18/05/2026
CBS LA has announced a multi-year partnership with the Los Angeles Rams, covering exclusive local broadcasts of Rams preseason games, weekly year-round programm...
18/05/2026
Skyline Communications has announced an integration between its DataMiner xOps p...
18/05/2026
eCLUTCH, the hybrid esports platform powered by iKOMG, has announced an expansion of its distribution across Europe, MENA, Africa, and Asia, along with new cont...
18/05/2026
Behind The Mic provides a roundup of recent news regarding on-air talent, includ...
18/05/2026
With 22 games this season, the production team looks forward to tweaking and enhancing the coverage
After 8,660 days off the air, the WNBA returned to NBC yest...
18/05/2026
(L-R) Midori Francis and Natalie Erika James attend the Saccharine premiere during the 2026 Sundance Film Festival at The Ray Theatre on January 22, 2026, in ...
18/05/2026
Last night, the Spotify Podcast Awards in Mexico returned to the country's capital. Now in its second year, the evening honors creators whose voices are hel...
18/05/2026
ZEN-Core synth goes mobile
Roland's powerful ZEN-Core software synthesizer has just been introduced to the iPad, offering a convenient entry point into ...
18/05/2026
Versatile new limiter plug-in announced
Based in Sheffield, UK, fedDSP offer a range of plug-ins that span the music production, live sound and high-end med...
18/05/2026
A new use for convolution?
Viiri Audio's debut plug-in aims to do something a little different with convolution processing, allowing users to adjust all...
18/05/2026
Delta Goodrem shines for SBS as more than 3.27 million Australians tune in for E...
18/05/2026
The Australian Defence Force uses L3Harris T4 and T7 robots for explosive ordnan...
18/05/2026
Continued investment across Europe and Germany is expanding local teams and improving access to stock, regional expertise, and specialist broadcast support.
CV...
18/05/2026
Agentic AI inference at one-tenth the cost per token with NVIDIA Vera Rubin NVL7...
18/05/2026
18 May 2026
Dubai and New York, May 18, 2026 - VEON Ltd. (NASDAQ: VEON), a glob...
18/05/2026
Monday 18 May 2026
Sky News offers ad-free podcasts and bonus episodes for just...
18/05/2026
Comscore March 2026 Consumer AI Chatbot Usage Rankings Show Claude Gaining Share OpenAI's ChatGPT maintains lead while Anthropic's Claude continues to c...
17/05/2026
Delta Goodrem's Eurovision Eclipse marks end of a stellar run
17 May, 2026
Media releases
Bulgaria wins Eurovision 2026
Relive every spellbinding mome...
17/05/2026
Back to All News
Oasis Premieres on Netflix June 19
Entertainment
17 May 2026
GlobalSpain
Link copied to clipboard
Summer, sunshine, the beach, parties. T...
16/05/2026
Helps to deliver a clean, balanced midrange
Developed alongside Newfangled Audio, the latest plug-in in Eventide's software collection has been designed...
16/05/2026
Brings onboard stem rendering to RANE System One
Engine DJ have just released Engine DJ 5.0, a free update for their Engine DJ OS embedded hardware and Engi...
16/05/2026
Boris FX Continuum Pairs AI Precision and Advanced Creative Controls
Jessie Electa Petrov May 16, 2026
0 Comments
The 2026.5 release adds automatic de...
16/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
16/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
16/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
16/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
15/05/2026
Seattle Sounders FC and Seattle Reign FC, in partnership with RAVE Foundation an...
15/05/2026
Dan Brumm has served as sound designer on Bluey, the Australian children's t...
15/05/2026
The Professional Audio Manufacturers Alliance (PAMA) and Shure Incorporated are accepting applications for the 6th annual Mark Brunner Professional Audio Schola...
FDA approves phase 1/2 clinical trial with ABX196 in patients with liver cancer ABX196 to be tested in combination with checkpoint inhibitor nivolumab to treat hepatocellular carcinoma
